Valeant Pharma (VRX) Reports Q2 EPS of $1.91
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Valeant (VRX) Price Target Reduced at Deutsche Bank
July 31, 2014 3:08 PM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and reduced its price target to $128.00 (from $133.00). The change follows its Q2 report. Analyst Gregg Gilbert described results as "ho-hum."
"While EPS of $1.91 came in line with our estimate (helped by lower tax rate), gross margin, operating income, and cash flow came in under our... More
Valeant Pharma (VRX) price drop a buying opportunity, Bill Ackman tells CNBC
July 31, 2014 12:19 PM EDTValeant Pharma (NYSE: VRX) price drop a buying opportunity, Bill Ackman tells CNBC. Shares are down nearly 7.6% following results.
... More